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Abstract 
Background: Ischemic insults during operation can cause ischemic‑reperfusion injuries in brain as well as memory 
impairments. Total intravenous anesthesia (TIVA) is the preferred anesthetic method in brain surgery, as it utilizes 
motor evoked potential monitoring. And the use of opioids is common in TIVA. However there are few studies about 
ischemic protective effect of opioids to glial cells.
Methods: We used mixed cultures of rat glial cells, which were harvested from the brain of 1‑day old rat. We divided 
the experimental groups according to their hydromorphone conditioning period: (a) pre‑culture, (b) per‑culture, or (c) 
pre‑ and per‑culture. We measured the levels of the reactive oxygen species (ROS) induced by tert‑butyl hydroperox‑
ide (TBH) using flow cytometry. The ROS levels in the glial cells were also measured after the administration of 100 nM 
hydromorphone and selective opioid receptor antagonists.
Results: The ROS levels were reduced in the hydromorphone‑treated group, as compared to the control group (only 
TBH treated). There were no differences between pre‑conditioned and per‑conditioned groups. However, the ROS 
levels were more reduced in pre‑ and per‑conditioned group compared to pre‑conditioned or per‑conditioned only 
groups. Furthermore, selective antagonists for the delta, kappa, or mu opioid receptor partially negated the hydro‑
morphone effect.
Conclusion: This study demonstrated that hydromorphone can have additional protective effects on oxidative stress 
when pre‑ and per‑conditioning is combined. Furthermore we proved that μ, δ, κ opioid receptors participate in 
protective mechanism of hydromorphone to glial cells.
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Background
In recent times, glial cells are considered to represent a 
specialized functional unit with neurons, in addition 
to providing neuronal support. Glial dysfunction can 
cause cognitive disorders as well as short-term memory 
loss (Vicente et al. 2009; Maragakis and Rothstein 2006). 
Ischemic shock during surgery can induce ischemic-rep-
erfusion injuries in the brain and memory impairments 
(Bilotta et  al. 2013). Many studies have established that 
opioids are protective against ischemia and reperfusion 
in different cell types (Gross et al. 2010; Goldsmith et al. 
2013). However, there are few studies that evaluate the 
protective effects of opioids in glial cells under ischemic 
conditions. Although opioids induce precondition-
ing effects in glial cells in the brain (Gwak et  al. 2010), 
it is unknown whether opioids also have perconditioning 
effects.
Currently, total intravenous anesthesia (TIVA) is the 
preferred technique of anesthesia during neurosurgery 
due to its use of motor evoked potential (MEP) moni-
toring (Scheufler and Zentner 2002). The perioperative 
use of opioids is common in such settings. Therefore, it 
is meaningful to investigate whether opioids possess pre- 
and per-conditioning effects on glial cells. In this study, 
we evaluated whether hydromorphone had pre- and per-
conditioning effect on glial cells. Furthermore we sought 
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to determine whether hydromorphone had additive 
effects when pre- and per-conditioning were combined.
Methods
Chemicals
Hydromorphone was purchased from Hanapharm 
Co. (Seoul, Korea). Tert-butyl hydroperoxide (TBH, 
t-BOOH) and 2′,7′-dichloroflurorescin diacetate (DCF-
DA) were purchased from Sigma Chemical Co. (St Louis, 
MO, USA). The anti-glial fibrillary acidic protein (GFAP) 
primary antibody and Alexa Fluor 488 goat anti-mouse 
antibody were purchased from Millipore Co. (Billerica, 
MA, USA) and Invitrogen Co. (Carlsbad, CA, USA), 
respectively. XTT was purchased from WELLGNE Inco. 
(Dalseo-gu, Daegu, Republic of Korea). The mounting 
solution was purchased from Vector Laboratories (Burl-
ingame, CA, USA).
Mixed primary rat glial cell culture
Rat glial cells were harvested and purified by the meth-
ods of previous study (de Vellis and Cole 2012). Pregnant 
Sprageue Dawley rat were purchased from Orientbio Co. 
(Seongnam-si, Gyeonggi-do, Republic of Korea). The rat 
cerebral cortices were purified from the brains of 1-day 
old rat pups, and then cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) media supplemented with 10 % 
fetal bovine serum, 1 % antibiotics at 37 °C, and 5 % CO2 
for 2 weeks. After 2 weeks, neurons, meningeal cells and 
fibroblasts were diminished, meanwhile microglial cells 
and astrocytes were replaced. We confirmed by immu-
nostaining with anti-GFAP primary antibody via confocal 
microscope (Nikon A1si, Nikon, Japan). All procedures 
were reviewed and approved by the Committee on the 
Ethics of Animal Experiments of the Korea University 
Medical School. (IRB KUIACUC-2015-253)
Cell viability
Cell viability was measured by XTT (2,3-bis-2-methoxy-
4-nitro-5-sulfophenyl-2H- tetrazolium-5-carboxanilide 
inner salt, WelCount Cell Viability Assay kit). The mixed 
glial cells were cultured in a 96-well plate. The control, 
TBH (100 µM) and/or hydromorphone (100 nM) treated 
glial cells were placed in a new DMEM media, containing 
a 5 % XTT reaction mixture (50:1 = XTT solution: PMS 
solution) and incubated in a CO2 incubator, at a tempera-
ture of 37 °C for a period of 2 h. The XTT assay generated 
formazan crystals, which were measured spectro-photo-
metrically with an ELISA reader (690 nm).
Experimental protocol
The production of ROS in mixed glial cells was induced 
by TBH, which is organic peroxide (Peters et  al. 2001), 
and then ROS was measured by flow cytometry using 
DCF-DA. The glial cells were proliferated to 5 × 104 cells 
in 6-well plates, and then transferred to a serum-free 
media, which was prepared by overnight serum starva-
tion. The cells were divided into 4 experimental groups : 
(1) pre-culture period (administration of 100 nM hydro-
morphone for 1 h, and then the media was changed to a 
serum-free media prior to 100  µM of TBH administra-
tion.); (2) per-culture period (100 nM of hydromorphone 
and 100 µM of TBH were co-treated.); (3) pre- and per-
culture (100  nM of hydromorphone was pretreated for 
1  h, and then the media was changed to a serum-free 
media. In addition, 100 µM of TBH and 100 nM of hydro-
morphone co-administrated for 30  min.); and (4) opioid 
receptor antagonist groups (pretreatment of 100  nM 
hydromorphone for 1 h, along with a selective delta- (δ-), 
kappa- (κ-), or mu-(μ-) opioid receptor antagonist, then 
cells were co-treated with TBH, opioid receptor antago-
nist, and 100 nM of hydromorphone) (Fig. 1). The dosage 
of opioid receptor antagonists were determined by previ-
ous study (Min et al. 2011). Also, Pilot study for determin-
ing the dosage of hydromorphone was performed. Three 
different doses (10, 100, 1000  nM) of hydromorphone 
were administrated. Each dosage of hydromorphone was 
treated for 1 h before 100 µM of TBH treatment (Fig. 2).
The measurement of the intracellular reactive oxygen 
species (ROS) production
Flow cytometry
The control-, TBH- (100  µM) and/or hydromorphone- 
(100 nM) treated glial cells were incubated in a CO2 incu-
bator with DCF-DA (10 µg/ml) at 37 °C for 20 min. The 
DCF-DA-treated glial cells were washed with phosphate-
buffered saline (PBS) and detached from the plate using 
trypsin–EDTA (0.25 %). The detached cells were diluted 
with PBS (300 µl) for analysis by flow cytometry. At least 
three different sets of experiments were performed using 
cells from different isolations.
TUNEL assay for apoptosis detection in glial cells
Apoptosis is characterized by DNA fragmentation, which 
can be detected by selective staining. A terminal deoxy-
nucleotidyltransferase-mediated dUTP nick end labeling 
(TUNEL) apopto-sis staining kit (Roche Molecular Bio-
chemicals, Mannheim, Ger-many) was used to detect 
programmed cell death. The glial cells were treated with 
hydromorphone (100  nM) for the pre-/per-period with 
TBH (100  µM) for 30  min), followed by fixation and 
TUNEL staining. The fixed cells were washed 3 times 
with PBS containing 0.1  %-Tween 20. The en-zyme and 
label solutions in the TUNEL stain kit were thoroughly 
mixed and reacted at 37  °C for 1 h. After the re-action, 
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the cells were washed 3 times with PBS containing 
0.1  %-Tween 20 and then examined using a confocal 
micro-scope. Three slides were examined for each group, 
and then particles were counted from 10 different parts 
of each slide.
Statistical analysis
We used SPSS (Windows version 10.0, Chicago, IL, 
USA) for statistical analysis. All results are expressed as a 
mean ± standard deviation (SD) and are representative of 
three different experiments. The flow cytometry results 
were evaluated by one-way Anova. P values greater than 
0.05 were considered significant.
Results
Cell viability
The cell survival rate after TBH was 84 %. This was calcu-
lated as a mean value.
Hydromorphone dosage
The cells that were treated with 100 or 1000  nM of 
hydromorphone had significantly lower levels of ROS 
Fig. 1 Experimental design. TBH: tert‑butyl hydroperoxide, DCF‑DA: 2′,7′‑dichloroflurorescin diacetate, OR antagonist : naltrindole (a selective delta 
opioid receptor antagonist) or nor‑binaltorphimine (a selective kappa opioid receptor antagonist) or naloxone
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compared to those in the TBH-treated group (Fig.  2). 
There were no differences between ROS levels in the 100 
and 1000 nM groups.
The effects of TBH and/or hydromorphone on reactive 
oxygen species (ROS) production
The ROS production was lower in the hydromorphone-
treated group compared to the control group treated 
with TBH only. Moreover, the ROS production was sig-
nificantly lower in the pre- and per-conditioned groups 
compared to the pre-conditioned or the per-conditioned 
alone groups (Fig. 3).
The effect of opioid antagonists on reactive oxygen species 
(ROS) production
The production of ROS was reduced in the hydromor-
phone-treated group. However, each of the selective δ-, 
κ-, and μ-opioid receptor antagonists partially negated 
the hydromorphone effects on ROS production (Fig. 4).
TUNEL assay in glial cells
The apoptotic cells appeared as light red dots under a fluo-
rescent microscope after performing the TUNEL as-say. A 
comparison between the TBH group and the pre- and per-
conditioned group revealed that there were significantly less 
apoptotic cells in the pre- and per-conditioned group. Fur-
thermore, the number of apoptotic cells in the opioid recep-
tor blocker group was significantly increased (Figs. 5, 6). 
Discussion
Currently, TIVA is the preferred method for general 
anesthesia during cerebral surgery because TIVA barely 
affects MEP monitoring (Zhang et  al. 2011, 2004). Opi-
oid use for intra-operative analgesia is common in TIVA. 
In this study, we demonstrated the pre-conditioning 
and per-conditioning effects of hydromorphone, pro-
viding evidence for the peri-operative effectiveness of 
hydromorphone.
Fig. 2 This graph shows effective dosage of hydromorphone for 
reducing ROS. The amount of ROS was expressed as Mean Fluores‑
cence index. *<0.05 versus TBH group. †<0.05 versus 10 nM hydro‑
morphone group
Fig. 3 Detection of intracellular ROS (reactive oxygen species) product. This graph shows the protective effect of hydromorphone on TBH induced 
toxicity in primary rat glial cell cultures. The ROS level was measured with using FACS (DCF‑DA) in the 100 nM hydromorphone (1) pre conditioned 
(2) per‑conditioned (3) pre‑ and per‑ conditioned primary rat glial cells. The amount of ROS was expressed as Mean Fluorescence index. *<0.05 
versus TBH group. †<0.05 versus preconditioning group. ‡<0.05 versus perconditioning group
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Recent studies have shown that opioids, including mor-
phine, have protective preconditioning effects in several 
ischemia/reperfusion models (Zhang et  al. 2011, 2004). 
Morphine has anti-neuroinflammatory properties and 
can prevent memory deficits due to its preconditioning 
effect, which is dependent on opioid receptors (Rostami 
et al. 2012). However, the role of opioids in glial cells is 
unclear. Although glial cells play an important role in the 
antioxidant defense system in the brain (Iwata-Ichikawa 
et  al. 1999), they are considered to be functional units 
rather than the barriers of neurons. Glial cell dysfunction 
can cause cognitive impairments and short-term mem-
ory loss (Vicente et  al. 2009; Maragakis and Rothstein 
2006). In addition, neuroinflammation is highly associ-
ated with ischemic stroke-induced cerebral damage and 
the progression of neurodegenerative diseases (Mucke 
and Eddleston 1993; Kreutzberg 1996; Brown and Bal-
Price 2003). Glial cells are important because they are 
responsible for the brain’s neurophysiology and hence, 
represent potential therapeutic targets.
Excessive oxidative stress produces excessive ROS. 
These ROS play important roles to CNS damage during 
ischemic conditions (Kontos 1989) and are associated 
with a variety of diseases (Hu et  al. 2015). Although a 
certain amount of ROS is essential for cellular survival, 
cell death can occur when ROS-induced oxidative stress 
exceeds a cell’s antioxidant capabilities (Hu et  al. 2015; 
Yan 2014). Excessive ROS production can cause DNA 
damage, modify protein and lipid functions, and activate 
signal pathways (Yan 2014). However, a moderate level of 
oxidative stress, referred to as positive oxidative stress, 
can be induced and modulated to produce an adaptive 
cellular response that is beneficial for cellular survival. 
Both preconditioning and per-conditioning effects can 
potentially be the result of positive oxidative stress (Yan 
2014; Milisav et al. 2012). Brief episodes of ischemia and 
reperfusion, and a number of pharmacological agents, 
can induce these phenomena (Das and Das 2008). TBH 
is commonly used to induce oxidative stress in vitro and 
in vivo (Rush et al. 1985). In this study, we used TBH to 
induce oxidative stress-related injury to rodent-derived 
glial cells (Holownia et al. 2009).
Several studies have demonstrated that morphine 
is involved in immune system functions (Hutchin-
son et  al. 2007; Madera-Salcedo et  al. 2011). Morphine 
exhibits both peripheral anti-inflammatory and inflam-
matory roles (Askari et  al. 2008; Pourpak et  al. 2004). 
Although opioids can induce glial activation and neu-
roinflammatory reactions (Watkins et  al. 2009), mor-
phine-induced preconditioning has been found to be 
Fig. 4 Effects of opioid receptor (OR) antagonists on reactive oxygen species (ROS) products. This graph shows that selective OR antagonists 
reverse the attenuation of the ROS induced by hydromorphone (pre and per‑condition). The ROS level was measured with using FACS (DCF‑DA) 
in the cells treated only TBH (control group), and the cells treated with TBH, hydromorphone and/or one of selective delta, kappa, and mu opioid 
receptor antagonists, naltrindole, nor‑binaltorphimine, and naloxone, respectively. The amount of ROS was expressed as Mean Fluorescence 
index.*<0.05 versus control group. +<0.05 versus hydromorphone group
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anti-neuroinflammatory (Rostami et  al. 2012). In these 
studies, we used hydromorphone, an opioid receptor 
agonist and morphine derivative (Ricket et  al. 2015), to 
prevent TBH-induced ROS production. Hydromor-
phone, one of the first line opioids as per the European 
guideline (Oosten et  al. 2015), is widely used for acute 
and chronic pain management in both adults and chil-
dren (Oosten et  al. 2015; Mherekumombe and Collins 
2015). Compared to morphine, hydromorphone has 
certain clinical advantages, such as reduced nausea and 
vomiting (Wirz et al. 2008), and lower histamine release 
(Guedes et al. 2007). To demonstrate its protective effect, 
we used hydromorphone to induce oxidative stress-
related injury. Because there are few in  vitro studies 
using hydromorphone, we choose an equi-analgesic dos-
age of hydromorphone as compared to morphine, based 
on previous studies (Min et  al. 2011; Lee et  al. 2012). 
Pilot studies determined the maximum effective dose of 
hydromorphone for a pre-/per-conditioning effect, which 
was 100 nM (Fig. 1).
In this study, hydromorphone was protective against 
TBH-induced oxidative stress-related injury. Interest-
ingly, the combined administration of hydromorphone 
(pre-conditioning followed by co-administration) had 
a superior effect compared to pre-conditioning and co-
administration treatments alone. Opioids can not only 
suppress responses to various noxious stimuli (e.g., short 
cyclic episodes of ischemia or ROS), but also have simi-
lar pre-conditioning effects (Rostami et al. 2012; Das and 
Das 2008). This cumulative effect of hydromorphone may 
be important for clinical settings, such as the periopera-
tive use of hydromorphone in neurosurgery.
The endogenous opioids and their receptors (μ-, δ-, 
κ-) are widely distributed in the glials like astrocytes 
(Pearce et  al. 1985), oligodendrocytes (Knapp et  al. 
1998) and microglial cells (Calvo et  al. 2000; Turchan-
Cholewo et  al. 2008). They exert their physiological 
effects, including nociception, analgesia, and brain 
development. Recently, Jeong et  al. (2012) reported 
that remifentanil which is selective agonist for δ-opioid 
receptor, has neuroprotective effect to both neurons and 
glial cells, improves neurological scores, and reduces 
infarct volumes via the attenuation of mitogen-activated 
protein kinases (MAPK). MAPK involves ROS produc-
tion and the release of pro-inflammatory cytokines (Son 
et al. 2011). But the protective effects of μ- and κ-opioid 
receptors to cerebral ischemia are still controversial. 
Some of studies have elucidated the protective function 
of κ-opioid receptors to reperfusion injury in ischemic 
cerebral animal models (Zhang et  al. 2003; Goyagi 
et  al. 2003). These effects are mediated through reduc-
ing NO production. Goyagi et  al. (2003) showed that 
(See figure on previous page.) 
Fig. 5 Terminal deoxynucleotidyl transferase‑mediated dUTP nick end labeling (TUNEL) assay of rat glial cells. a Fluorescence micrographs of cells 
were stained with rhodamine and DAPI. Red particles represent DNA fragments. This graphs show the Control, TBH, and Hydromorphone groups. 
b Fluorescence micrographs of cells were stained with rhodamine and DAPI. Red particles represent DNA fragments. This graphs show the opioid 
antagonist groups. †<0.05 versus hydromorphone group
Fig. 6 Terminal deoxynucleotidyl transferase‑mediated dUTP nick end labeling (TUNEL) assay of rat glial cells. a This graph shows quantitation of 
apoptotic cells from TUNEL assay by number of red particles. *<0.05 versus TBH group. †<0.05 versus hydromorphone group
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activation of κ-opioid receptors attenuates the evoka-
tion of NMDA by inhibiting excitatory postsynaptic 
potentials, and NMDA is involved in the NO produc-
tion of brain. NMDA receptors are abundant in glial cells 
and neurons, and have important roles to maintain the 
homeostasis of brain (Verkhrataky and Kirchhoff 2007). 
These evoked N-Methyl-d-aspartic acid (NMDA) also 
induces ROS products (Shelat et  al. 2008). Our results 
demonstrate that each opioid receptor subtype, the μ-, 
δ-, and κ-opioid receptor, reduces ROS production and 
is involved in the protective effects of hydromorphone in 
mixed glial cells. After administration of selective μ-, δ-, 
and κ-opioid receptor antagonists, ROS production was 
similar to that of the TBH-treated group, suggesting that 
the μ-, δ-, and κ-opioid receptors all contribute to hydro-
morphone’s protective effects. Our data also suggest that 
hydromorphone has pre and per conditioning effects as 
well. Considering the present results, MAPK pathways 
and NMDA signaling pathways might be involved in the 
protective effect of hydromorphone on TBH-induced 
glial cells. Further studies are required to evaluate the 
mechanism underlying opioid receptors involvement by 
using knockout models.
In conclusion, this study provides evidence that hydro-
morphone has both, pre-conditioning and per-condition-
ing effects on the TBH-induced injuries. Furthermore, 
pre- and per-conditioning effects of hydromorphone 
is additive. We also demonstrated that the μ-, δ-, and 
κ-opioid receptors all contributes to the mechanism of 
hydromorphone and its protective effect on glial cells. 
Hence, our findings support the therapeutic potential for 
hydromorphone in the prevention of ischemic cerebral 
injury during the perioperative period.
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